摘要
免疫检查点抑制剂(ICI)是一种通过抑制免疫检查点活性恢复并提高T淋巴细胞特异性识别及杀死肿瘤细胞能力的单克隆抗体,是近年来恶性肿瘤治疗领域的突破性进展。ICI相关心肌炎(ICI-M)是ICI导致的一种起病急、症状重、进展迅速的免疫相关不良事件,但目前临床医师对ICI-M的认知不足。本文综述了近年来ICI-M的流行病学、发病机制、诊断和治疗等方面的研究进展。
Immune checkpoint inhibitors(ICI)are monoclonal antibodies that could restore and improve the ability of T lymphocytes to specifically recognize and kill tumor cells by inhibiting immune checkpoint activity,this therapeutic strategy is a breakthrough in the treatment of malignant solid tumors in recent years.ICI–associated myocarditis(ICI-M)is one of the immune-related adverse events with rapid onset,severe symptoms and rapid progression.However,the clinical understanding of ICI-M is insufficient at present.This article reviews current research progress on epidemiology,pathogenic mechanism,diagnosis and treatment of ICI-M.
作者
闫静静
刘韶瑜
葛洪霞
马青变
YAN Jingjing;LIU Shaoyu;GE Hongxia;MA Qingbian(Department of Emergency,Key Laboratory of Molecular Cardiovascular Sciences,Ministry of Education,Peking University Third Hospital,Beijing 100191,China)
出处
《中国循环杂志》
北大核心
2025年第2期197-202,共6页
Chinese Circulation Journal
基金
国家临床重点专科建设项目(2022)专项资金(301-2305)。
关键词
免疫检查点抑制剂
心肌炎
免疫相关不良事件
心脏毒性
immune checkpoint inhibitor
myocarditis
immune-related adverse event
cardiac toxicity
作者简介
通信作者:刘韶瑜,Email:lsy505@163.com。
